FDA approves reduced sample size for X4's 4WARD trial

X4 Pharmaceuticals secured FDA agreement to reduce its late-stage trial enrollment by 126 patients, with data expected mid-2028. This regulatory alignment supports the company's expanded mavorixafor franchise for antibody deficiencies.